CST, 54721SF, Vitamin D3 Receptor (D2K6W) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying Vitamin D3 Receptor. Validated for Western Blotting,Immunohistochemistry (Paraffin). Highly specific and rigorously validated in-house, Vitamin D3 Receptor (D2K6W) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #54721) is ready to ship. Product Usage Information This product is the carrier free version of product #12550. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 12550 . Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity Vitamin D3 Receptor (D2K6W) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total vitamin D3 receptor protein. This antibody does not cross-react with vitamin D3 receptor-like proteins. Based upon sequence alignment, this antibody is predicted to react with both VDRB1 and VDRB2 isoforms. Species Reactivity: Human, Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human vitamin D3 receptor isoform A protein. Background Although originally identified based on their roles in calcium and bone homeostasis, the vitamin D3 receptor (VDR/NR1I1) and its ligand 1-α, 25-dihydroxycholecalciferol [1α, 25(OH) D ] are now recognized to exert biological effects in almost every tissue of the human body. Targets for vitamin D signaling include the central nervous system, skin, immune system, endocrine glands, kidney, and colon. At the cellular level, vitamin D signaling affects proliferation, differentiation, and apoptosis of both normal and transformed cells. Within the steroid receptor gene family, VDR belongs to the NR1I subfamily that also includes NR1I2/PXR and NR1I3/CAR. The human gene is composed of 11 exons that encode six domains (A-F) of the full length VDR protein, which includes an N-terminal dual zinc finger DNA binding domain, a C-terminal ligand-binding activity domain, and an extensive unstructured region that links the two functional domains together (1). Upon 1α, 25(OH) D binding to the hormone ligand-binding domain, VDR is stabilized by the phosphorylation of Ser51 in the DNA-binding domain by PKC (2), and Ser208 in the hinge region by casein kinase II (3). VDR associates with the retinoic acid receptor (RXR) through dimerization domains. The 1α, 25(OH) D -VDR-RXR complex binds to the vitamin D response elements (VDREs) in the promoters of target genes through the DNA-binding domain. Ligand-induced conformation changes in VDR results in the dissociation of the co-repressor, silencing-mediator for retinoid and thyroid hormone receptors (SMRT), and allows interaction of the VDR activation function (AF2) transactivation domain with transcriptional coactivators (1).Studies have shown that variable VDR expression is associated with different forms or stages of cancer and likely results from tissue-type variation in 1α, 25(OH) D signaling. In the case of colon cancer, research indicates that VDR expression is relatively higher in hyperplastic colon polyps and during early tumorigenesis but diminishes in later stage, poorly differentiated tumors. Multiple studies suggest that 1α, 25(OH) D may be an attractive target for development as a therapeutic anticancer agent (4,5) . Alternate Names 1,25-dihydroxyvitamin D3 receptor; NR1I1; nuclear receptor subfamily 1 group I member 1; PPP1R163; protein phosphatase 1, regulatory subunit 163; VDR; vitamin D (1,25- dihydroxyvitamin D3) receptor; vitamin D nuclear receptor variant 1; vitamin D receptor; Vitamin D3 receptor Specification REACTIVITY: H M SENSITIVITY: Endogenous MW (kDa): 48, 54 Source/Isotype: Rabbit IgG